Pre-made Spartalizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-531

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-531 Category Tag

Product Details

Pre-Made Spartalizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Spartalizumab (INN; development code PDR001) is a monoclonal antibody that is being investigated for melanoma.

Products Name (INN Index)

Pre-Made Spartalizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody

INN Name

Spartalizumab

Target

PDCD1

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2017

Companies

Asan Medical Center,Dana-Farber Cancer Institute,Novartis,Novartis Oncology,Palobiofarma,Seoul National University Hospital

Conditions Approved

NA

Conditions Active

Malignant melanoma,Breast cancer,Colorectal cancer,Diffuse large B cell lymphoma,Gastric cancer,Nasopharyngeal cancer,Non-small cell lung cancer,Solid tumours,Acute myeloid leukaemia,Cancer,Liver can

Conditions Discontinued

Neuroendocrine tumours

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

PDCD1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide